リスジプラム
353FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with type 1 spinal muscular atrophy”. Neuromuscular Disorders (London, United Kingdom of Great Britain: World Muscle Society (WMS)/Elsevier Inc.) 29 (Supplement 1): S184. doi:10.1016/j.nmd.2019.06.515. ISSN 0960-8966. OCLC 24318845.
1 2 “Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)”. Neurology (Minneapolis, Minnesota, United States of America: American Academy of Neurology/Wolters Kluwer) 92 (15 (Supplement)). (16 April 2019). ISSN 00283878. LCCN 55-43902. OCLC 960771045. https://n.
Dhillon S (November 2020). “Risdiplam: First Approval” (English). Drugs (Berlin, Germany/Heidelberg, Germany/Cham, Switzerland: Adis International/Springer Nature Switzerland AG (Springer Nature)) 80 (17): 1853-1858. doi:10.1007/s40265-020-01410-z. OCLC 01566990. PMID 33044711.
Ratni H, Scalco RS, Stephan AH (28 January 2021). “Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines”. ACS Medicinal Chemistry Letters (Washington, D.C.: ACS Publications (American Chemical Society)) 12 (6): 11021-11036. doi:10.1021/acsmedchemlett.0c00659. ISSN 19485875. OCLC 643819990. PMC 8201486. PMID 34141064. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201486/.